Synthetic, topically delivered innate immunomodulators

ENA Respiratory is focused on developing innovative innate immune enhancers aimed at preventing complications from respiratory viral infections, particularly in at-risk populations. Their lead product, INNA-051, is a first-in-class TLR2/6 agonist designed for self-administration via the nasal route, with a convenient weekly dosing schedule. This novel therapeutic approach works by priming the body's innate immune response at the upper respiratory tract, which is the primary entry point for viral infections. By enhancing the immune response, INNA-051 facilitates faster viral clearance and minimizes the risk of the virus spreading to the lower airways, thereby potentially reducing the severity of respiratory illnesses.

The clinical development of INNA-051 is backed by a team of experienced clinicians and drug developers who possess extensive knowledge of respiratory diseases. The product has shown efficacy against multiple respiratory viruses and boasts a favorable safety profile, making it suitable for seasonal prophylactic use. The rapid onset of action and sustained immune response further support its weekly dosing regimen, positioning INNA-051 as a promising option for improving health outcomes in vulnerable populations and alleviating the burden on healthcare systems.

Australia

ENA Respiratory is a clinical stage pharmaceutical company, developing INNA-051, a topical, broad spectrum antiviral immunomodulator for pre- and post-exposure prophylaxis of respiratory viral infections

Ena Respiratory

Company Details